(NYSE: OGN) Organon & Co's forecast annual revenue growth rate of -0.19% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Organon & Co's revenue in 2025 is $6,301,000,000.On average, 8 Wall Street analysts forecast OGN's revenue for 2025 to be $1,638,152,328,512, with the lowest OGN revenue forecast at $1,579,656,173,312, and the highest OGN revenue forecast at $1,709,647,629,312. On average, 8 Wall Street analysts forecast OGN's revenue for 2026 to be $1,622,813,336,704, with the lowest OGN revenue forecast at $1,512,580,582,016, and the highest OGN revenue forecast at $1,729,406,330,624.
In 2027, OGN is forecast to generate $1,634,512,567,744 in revenue, with the lowest revenue forecast at $1,507,380,923,776 and the highest revenue forecast at $1,753,844,724,352.